Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPARE trial in Crohn's disease remission on infliximab + antimetabolite therapy
NL-OMON46754Phase 4Active, not recruiting
- Sponsor
- GETAID
- Start
- Sep 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of infliximab, azathioprine, mercaptopurine and methotrexate in Crohn's disease (3 arms), sponsored by GETAID. Primary endpoints: Relapse rate at 2 years and Mean restricted time spent in remission. Started Sep 2018; status: active, not recruiting.
02
Drugs
infliximabazathioprinemercaptopurinemethotrexate
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON46754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46754.